Safety assessment
ADVERSE EVENTS
Vital signs such as blood pressure, pulse, respiration and oxygen saturation were measured in the supine position for the subjects 1 h before and 1, 2, 4, 8, 12, 24, 48 and 72 h after administration. Routine blood tests, electrocardiograms, blood biochemistry and urine tests were performed 24 h before and 72 h after administration. The symptoms of injection sites were recorded, and irritation was assessed at 0.5 h before and 0.3, 0.6, 1, 2, 6, 24 and 72 h after administration. The criteria for local adverse events are shown in 